Key points are not available for this paper at this time.
In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-naïve patients with ulcerative proctitis.
Dalal et al. (Fri,) studied this question.